Circulating immune checkpoints predict heart failure outcomes

Circulating immune checkpoints predict heart failure outcomes

Abstract Aims There are limited data examining the role of immune checkpoint (IC) ligands in the pathophysiology of heart failure (HF). Therefore, we explore this in three HF animal models and in three different human cohorts (healthy, stable, and worsening HF). Methods and results Transcriptomic an...

Bibliografiset tiedot
Päätekijät:	Elles M. Screever, Laura I.E. Yousif, Javid J. Moslehi, Joe‐Elie Salem, Adriaan A. Voors, Herman H.W. Silljé, Rudolf A. deBoer, Wouter C. Meijers
Aineistotyyppi:	Artikkeli
Kieli:	English
Julkaistu:	Wiley 2023-08-01
Sarja:	ESC Heart Failure
Aiheet:	Immune checkpoints PD‐L1 PD‐L2 Galectin‐9 Heart failure
Linkit:	https://doi.org/10.1002/ehf2.14304

Samankaltaisia teoksia

Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study
Tekijä: Douglas B. Johnson, et al.
Julkaistu: (2019-05-01)

Checkpoint Inhibition in Myeloma: Opportunities and Challenges
Tekijä: Federica Costa, et al.
Julkaistu: (2018-09-01)

The role of immune checkpoints in cardiovascular disease
Tekijä: Laura I. Yousif, et al.
Julkaistu: (2022-10-01)

Enhancing cancer care with improved checkpoint inhibitors
Tekijä: Vickram A S, et al.
Julkaistu: (2024-10-01)

Checkmate with checkpoint inhibitors: New paradigm in immunotherapy
Tekijä: Ruby Dhar, et al.
Julkaistu: (2023-04-01)

Characterization of PD-1/PD-L1 Immune Checkpoint Expression in Osteosarcoma
Tekijä: Kazuhiko Hashimoto, et al.
Julkaistu: (2020-07-01)

Immune Checkpoint in Glioblastoma: Promising and Challenging
Tekijä: Jing Huang, et al.
Julkaistu: (2017-05-01)

Phytochemicals in Cancer Immune Checkpoint Inhibitor Therapy
Tekijä: Juwon Lee, et al.
Julkaistu: (2021-07-01)

Overview of the Cardiotoxicity Induced by PD-1/PD-L1 Immune Checkpoint Inhibitor in Critical Care
Tekijä: Ruiting Li, et al.
Julkaistu: (2021-06-01)

On Demand Biosensors for Early Diagnosis of Cancer and Immune Checkpoints Blockade Therapy Monitoring from Liquid Biopsy
Tekijä: Sai Mummareddy, et al.
Julkaistu: (2021-12-01)

PD-1/PD-L1 immune checkpoint inhibitors in glioblastoma: clinical studies, challenges and potential
Tekijä: Tianrui Yang, et al.
Julkaistu: (2021-02-01)

PD-L1 expression on malignant cells is no prerequisite for checkpoint therapy
Tekijä: Jan Willem Kleinovink, et al.
Julkaistu: (2017-04-01)

Epigenetic modifications of the immune-checkpoint genes CTLA4 and PDCD1 in non-small cell lung cancer results in increased expression
Tekijä: Sebastian Marwitz, et al.
Julkaistu: (2017-05-01)

Immune Checkpoint Inhibitors in Cancer Therapy
Tekijä: Yavar Shiravand, et al.
Julkaistu: (2022-04-01)

Research Progress on Cardiotoxicity of PD-1/PD-L1 Immune Checkpoint Inhibitors
Tekijä: YU Lin, et al.
Julkaistu: (2021-08-01)

The Role of Immune Checkpoint Inhibitors in Cancer Therapy
Tekijä: Ahmed M. Basudan
Julkaistu: (2022-12-01)

The role of immune checkpoint inhibitors in prostate cancer
Tekijä: Gabriel Surdacki, et al.
Julkaistu: (2019-03-01)

Editorial: The Roles of Checkpoint Inhibitors in Inflammatory Diseases
Tekijä: Andreas von Knethen, et al.
Julkaistu: (2021-10-01)

Activity and Safety of Immune Checkpoint Inhibitors in Neuroendocrine Neoplasms: A Systematic Review and Meta-Analysis
Tekijä: Alberto Bongiovanni, et al.
Julkaistu: (2021-05-01)

Predictive Biomarkers of Immune Checkpoint Inhibitors-Related Toxicities
Tekijä: Ya Xu, et al.
Julkaistu: (2020-10-01)

Structural Characterization of a Macrocyclic Peptide Modulator of the PD-1/PD-L1 Immune Checkpoint Axis
Tekijä: Edyta Zyla, et al.
Julkaistu: (2021-08-01)

The Neonatal Innate Immune Response to Sepsis: Checkpoint Proteins as Novel Mediators of This Response and as Possible Therapeutic/Diagnostic Levers
Tekijä: Emily Hensler, et al.
Julkaistu: (2022-07-01)

Key questions about the checkpoint blockade-are microRNAs an answer?
Tekijä: Mihnea Dragomir, et al.
Julkaistu: (2018-06-01)

Vascular Targeting to Increase the Efficiency of Immune Checkpoint Blockade in Cancer
Tekijä: Maria Georganaki, et al.
Julkaistu: (2018-12-01)

Enhancement of anti-tumor efficacy of immune checkpoint blockade by alpha-TEA
Tekijä: William L. Redmond, et al.
Julkaistu: (2023-02-01)

The epigenetic immunomodulator, HBI-8000, enhances the response and reverses resistance to checkpoint inhibitors
Tekijä: Reid P. Bissonnette, et al.
Julkaistu: (2021-08-01)

Advances in immune checkpoint inhibitors for hepatocellular carcinoma
Tekijä: Ji Won Han, et al.
Julkaistu: (2021-09-01)

Immune Checkpoint Inhibitors: Ctla-4 and Pd-1/Pd-l1 in Immunotherapy
Tekijä: Kübra KAHVECİ, et al.
Julkaistu: (2019-12-01)

Radiation, Immune Checkpoint Blockade and the Abscopal Effect: A Critical Review on Timing, Dose and Fractionation
Tekijä: Zachary S. Buchwald, et al.
Julkaistu: (2018-12-01)

Safety and efficacy of PD-1/PD-L1 immune checkpoint inhibitors in patients with pre-treated advanced stage malignant mesothelioma: a systematic review and meta-analysis
Tekijä: Amjad Zafar, et al.
Julkaistu: (2024-11-01)

The impact of antibiotic use on clinical features and survival outcomes of cancer patients treated with immune checkpoint inhibitors
Tekijä: Jiaxin Zhou, et al.
Julkaistu: (2022-07-01)

Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons
Tekijä: Adel Naimi, et al.
Julkaistu: (2022-04-01)

Editorial: Biomarkers of Immune-Checkpoint-Inhibitor Immunotherapies in Hepatocellular Carcinomas
Tekijä: Zhanjun Guo, et al.
Julkaistu: (2022-03-01)

Profiling targetable immune checkpoints in osteosarcoma
Tekijä: Troy A McEachron, et al.
Julkaistu: (2018-12-01)

The Use of Phytochemicals to Improve the Efficacy of Immune Checkpoint Inhibitors: Opportunities and Challenges
Tekijä: Deniz Can Guven, et al.
Julkaistu: (2022-10-01)

Commentary: Chronic PD-1 Checkpoint Blockade Does Not Affect Cognition or Promote Tau Clearance in a Tauopathy Mouse Model
Tekijä: Kuti Baruch, et al.
Julkaistu: (2020-05-01)

NSCLC: from tumorigenesis, immune checkpoint misuse to current and future targeted therapy
Tekijä: Leona Raskova Kafkova, et al.
Julkaistu: (2024-02-01)

Efficacy and safety of immune checkpoint inhibitors in non-small cell lung cancer
Tekijä: Shuai Wang, et al.
Julkaistu: (2018-08-01)

PD/1-PD-Ls Checkpoint: Insight on the Potential Role of NK Cells
Tekijä: Silvia Pesce, et al.
Julkaistu: (2019-06-01)

In Search of Better Peptide-(Derived from PD-L2)-Based Immune Checkpoint Inhibitors
Tekijä: Boris Klebansky, et al.
Julkaistu: (2024-05-01)